Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 4
1969 2
1974 2
1975 1
1976 1
1979 2
1980 2
1982 1
1983 4
1986 2
1987 3
1988 1
1989 3
1990 4
1991 2
1992 3
1993 5
1994 4
1995 8
1996 7
1997 5
1998 4
1999 9
2001 2
2002 1
2003 3
2004 1
2005 5
2006 2
2007 1
2008 2
2010 3
2011 5
2012 1
2013 5
2014 2
2015 4
2016 6
2017 4
2018 15
2019 5
2020 5
2021 1
2022 3
2023 3
2024 1
2025 2
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

151 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and Safety of Oxymetazoline 1% Cream for the Treatment of Mild to Moderate Facial Rosacea.
Sajdeh F, Samadi A, Naeimifar A, Yazdanparast T, Ahmadi M, Amiri F, Kassir M, Firooz A, Nasrollahi SA. Sajdeh F, et al. J Cosmet Dermatol. 2025 Apr;24(4):e16782. doi: 10.1111/jocd.16782. J Cosmet Dermatol. 2025. PMID: 40165547 Free PMC article. Clinical Trial.
The objective of this study was to evaluate the efficacy and safety of oxymetazoline 1% cream, a specific alpha1A-adrenoceptor agonist, for the treatment of mild to moderate facial rosacea. ...No side effects of treatment were experienced by any of the patients. CONCLUSION …
The objective of this study was to evaluate the efficacy and safety of oxymetazoline 1% cream, a specific alpha1A-adrenoceptor agonis …
The effects of topical oxymetazoline on eyelid position, eye redness, and patient-reported eye appearance: A randomized controlled trial.
Shoji MK, Markatia Z, Ameli K, Bayaraa M, Clauss KD, Ugradar S, Lee WW. Shoji MK, et al. J Plast Reconstr Aesthet Surg. 2023 May;80:66-74. doi: 10.1016/j.bjps.2023.02.006. Epub 2023 Feb 9. J Plast Reconstr Aesthet Surg. 2023. PMID: 36996503 Free article. Clinical Trial.
PURPOSE: This study assesses the effects of topical oxymetazoline 0.1% on eyelid position, eye redness, and patient-perceived eye appearance in patients without severe ptosis. ...Patients aged 18-100 years were randomized to receive one drop of oxymetazoline hydroch …
PURPOSE: This study assesses the effects of topical oxymetazoline 0.1% on eyelid position, eye redness, and patient-perceived eye app …
A Randomized Controlled Pilot Study: Combined 595-nm Pulsed Dye Laser Treatment and Oxymetazoline Hydrochloride Topical Cream Superior to Oxymetazoline Hydrochloride Cream for Erythematotelangiectatic Rosacea.
Sodha P, Suggs A, Munavalli GS, Friedman PM. Sodha P, et al. Lasers Surg Med. 2021 Dec;53(10):1307-1315. doi: 10.1002/lsm.23439. Epub 2021 Jul 7. Lasers Surg Med. 2021. PMID: 34233378 Free PMC article. Clinical Trial.
BACKGROUND AND OBJECTIVES: We evaluated if oxymetazoline therapy combined with 595-nm pulsed dye laser (PDL) will be more beneficial than topical oxymetazoline alone for the improvement of erythematotelangiectatic rosacea. STUDY DESIGN/MATERIALS AND METHODS: This wa …
BACKGROUND AND OBJECTIVES: We evaluated if oxymetazoline therapy combined with 595-nm pulsed dye laser (PDL) will be more beneficial …
Use of an alternative method to evaluate erythema severity in a clinical trial: difference in vehicle response with evaluation of baseline and postdose photographs for effect of oxymetazoline cream 1.0% for persistent erythema of rosacea in a phase IV study.
Eichenfield LF, Del Rosso JQ, Tan JKL, Hebert AA, Webster GF, Harper J, Baldwin HE, Kircik LH, Stein-Gold L, Kaoukhov A, Alvandi N. Eichenfield LF, et al. Br J Dermatol. 2019 May;180(5):1050-1057. doi: 10.1111/bjd.17462. Epub 2019 Feb 27. Br J Dermatol. 2019. PMID: 30500065 Free PMC article. Clinical Trial.
BACKGROUND: Once-daily topical oxymetazoline cream 1.0% significantly reduced persistent facial erythema of rosacea in trials requiring live, static patient assessments. ...RESULTS: Among 835 patients (oxymetazoline n = 415, vehicle n = 420), significantly greater p …
BACKGROUND: Once-daily topical oxymetazoline cream 1.0% significantly reduced persistent facial erythema of rosacea in trials requiri …
Pivotal Trial of the Efficacy and Safety of Oxymetazoline Cream 1.0% for the Treatment of Persistent Facial Erythema Associated With Rosacea: Findings from the Second REVEAL Trial.
Baumann L, Goldberg DJ, Stein Gold L, Tanghetti EA, Lain E, Kaufman J, Weng E, Berk DR, Ahluwalia G. Baumann L, et al. J Drugs Dermatol. 2018 Mar 1;17(3):290-298. J Drugs Dermatol. 2018. PMID: 29537447 Clinical Trial.
The proportion of patients achieving the primary efficacy outcome was significantly greater with oxymetazoline versus vehicle (P=0.001). Similar results favoring oxymetazoline over vehicle were observed for the individual CEA and SSA scores (P less than 0.001 and P= …
The proportion of patients achieving the primary efficacy outcome was significantly greater with oxymetazoline versus vehicle (P=0.00 …
Hemodynamic and pharmacokinetic analysis of oxymetazoline use during nasal surgery in children.
Cartabuke RS, Anderson BJ, Elmaraghy C, Rice J, Tumin D, Tobias JD. Cartabuke RS, et al. Laryngoscope. 2019 Dec;129(12):2775-2781. doi: 10.1002/lary.27760. Epub 2019 Feb 20. Laryngoscope. 2019. PMID: 30786035 Free PMC article. Clinical Trial.
Mean arterial pressure did not increase with oxymetazoline instillation at the observed oxymetazoline serum concentrations (0.04-7.6 mug/L). CONCLUSIONS: Despite concerns regarding oxymetazoline administration to mucosal membranes, we found that hemodynamic c …
Mean arterial pressure did not increase with oxymetazoline instillation at the observed oxymetazoline serum concentrations (0. …
Pharmacokinetics of Nasal Esketamine in Patients with Allergic Rhinitis with and Without Nasal Decongestant Pretreatment and in Healthy Subjects with and Without Nasal Corticosteroid Pretreatment.
Zannikos P, Solanki B, De Meulder M, Badorrek P, Hohlfeld JM, Singh J. Zannikos P, et al. Clin Pharmacokinet. 2023 Sep;62(9):1315-1328. doi: 10.1007/s40262-023-01273-z. Epub 2023 Jul 4. Clin Pharmacokinet. 2023. PMID: 37402024 Clinical Trial.
METHODS: Patients with allergic rhinitis self-administered 56 mg of nasal esketamine after pretreatment with nasal oxymetazoline (0.05%) at 1 h before esketamine and without oxymetazoline pretreatment. They were exposed to grass pollen in an allergen challenge chamb …
METHODS: Patients with allergic rhinitis self-administered 56 mg of nasal esketamine after pretreatment with nasal oxymetazoline (0.0 …
[Tolerance and effectiveness of oxymetazoline and xylometazoline in treatment of acute rhinitis].
Dorn M, Hofmann W, Knick E. Dorn M, et al. HNO. 2003 Oct;51(10):794-9. doi: 10.1007/s00106-003-0869-z. HNO. 2003. PMID: 14523532 Clinical Trial. German.
PATIENTS AND METHOD: A total of 307 patients with acute rhinitis entered the study. The treatment with oxymetazoline with preservative, oxymetazoline without preservative and xylometazoline with preservative was evaluated. RESULTS: This randomised, double-blind, mul …
PATIENTS AND METHOD: A total of 307 patients with acute rhinitis entered the study. The treatment with oxymetazoline with preservativ …
Efficacy and safety of oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: Findings from the 52-week open label REVEAL trial.
Draelos ZD, Gold MH, Weiss RA, Baumann L, Grekin SK, Robinson DM, Kempers SE, Alvandi N, Weng E, Berk DR, Ahluwalia G. Draelos ZD, et al. J Am Acad Dermatol. 2018 Jun;78(6):1156-1163. doi: 10.1016/j.jaad.2018.01.027. Epub 2018 Jan 31. J Am Acad Dermatol. 2018. PMID: 29409914 Free article. Clinical Trial.
OBJECTIVE: To examine the long-term safety and efficacy of oxymetazoline cream 1.0% in patients with rosacea with moderate-to-severe persistent erythema. ...CONCLUSION: This long-term study demonstrated sustained safety, tolerability, and efficacy of oxymetazoline f …
OBJECTIVE: To examine the long-term safety and efficacy of oxymetazoline cream 1.0% in patients with rosacea with moderate-to-severe …
151 results